Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525126 | 0.89 | RAB9A (0.36) | KMT2ARAB9ANPC1ALDH1A1HTT | |
| SCHEMBL2526408 | 0.88 | RAB9A (0.35) | PYGLKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL2522895 | 0.86 | AAK1 (0.40) | PYGLKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL2520920 | 0.83 | ALDH1A1 (0.42) | RAB9AALDH1A1HTTERCC1ERCC4 | |
| SCHEMBL15929315 | 0.80 | LIPG (0.45) | PYGLKMT2ARAB9ANPC1MEN1 | |
| SCHEMBL2523277 | 0.78 | AAK1 (0.39) | KMT2ARAB9AALDH1A1HTTMEN1 | |
| SCHEMBL2523924 | 0.77 | AAK1 (0.38) | — | |
| SCHEMBL2527558 | 0.77 | KMT2A (0.42) | PYGLKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL2524662 | 0.74 | TSHR (0.43) | KMT2ARAB9AALDH1A1MEN1KDM4E | |
| SCHEMBL18485841 | 0.73 | TDP1 (0.36) | KMT2ARAB9ANPC1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251173-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-10-13 | — | — | US | disclosed |
| WO-2011121350-A1 | 4 -AMINO -7,8- DIHYDROPYRIMIDO [5, 4 - F] [1, 4] OXAZEPIN- 5 ( 6H) - ONE BASED DGAT1 INHIBITORS | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251173-A1 | CHEMICAL COMPOUNDS | DGAT1, DGAT2, SLC5A1 | PYGL 742/4885KMT2A 2289/4885RAB9A 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.